Immunovant
Drug Discovery · Biologics & Biosimilars
7open roles
$240kmedian advertised pay
500+people
3cities with offices
Overview
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases.
Jobs
$170k – $200k per year · Remote (likely United States) · Bachelor's Degree
Apply
$160k – $180k per year · Remote (likely United States) · 3+ years exp · Bachelor's Degree
Apply
$280k – $320k per year · Remote (likely United States) · 15+ years exp · Master's Degree
Apply
$200k – $240k per year · Remote (likely United States) · 10+ years exp · Bachelor's Degree
Python
PowerShell
Model Context Protocol
DevOps
Terraform
Azure
CI/CD
Docker
Kubernetes
Azure AKS
GitHub
Cybersecurity
Okta
Zscaler
Zero Trust
Management
Service Desk
Apply
$200k – $235k per year · Remote (likely United States) · 10+ years exp · Bachelor's Degree
SQL
Tableau
Power BI
Microsoft Excel
Management
SharePoint
Life Sciences
GMP
Apply
$260k – $295k per year · Remote (likely United States) · 12+ years exp · Bachelor's Degree
Veeva
Apply
$175k – $195k per year · Remote (likely United States) · 10+ years exp · Bachelor's Degree
SAS
CDISC
Apply
Salary insights
Compensation ranges based on this company's open jobs
Median
$240k
Typical range
$150k – $320k
Open positions
11
11
Jobs
Senior
36.4%
Architect
63.6%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Senior | 4 | $188k | $150k – $295k |
| Architect | 7 | $240k | $200k – $320k |
Highest paying role
Executive Director, New Product Planning
$320k
Normalized to USD per year
All salaries at Immunovant
By role, level and city, against the market · 11 jobs with pay
Growth
Hiring Momentum
23/100
Hiring freeze
Open positions
11
0 opened / 0 closed in 30 days
Median time-to-fill
60 days
faster than 22% of the market
ATS activity
Every ~5 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Leadership
27% ▼
Operations
27% ▼
Finance
9% ▲
Management
9% ▲
Marketing
9% ▲
Early Careers
9% ▲
Financials
Total raised
$450M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2025 | $450M | Details |
People
Christopher Van Tuyl
Executive Officer
Michael Geffner
Executive Officer
Pete Salzmann
Executive Officer, Director
Jay Stout
Executive Officer
Melanie Gloria
Executive Officer
Eva Renee Barnett
Executive Officer
Bill Macias
Executive Officer
Andrew Fromkin
Director
Atul Pande
Director
George Migausky
Director
Eric Venker
Director
Frank Torti
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Tech stack
Technologies named in job postings at Immunovant over the last 12 months, by layer, with the share of postings for each.
Technologies in use
21
Postings analysed
6
Stack modernity
71/100
Languages
PowerShell
Python
SAS
SQL
Cloud & platforms
Azure
Azure AKS
GCP
GitHub
Sign in to see how your skills match this stack
Sign In
Full Immunovant tech stack
21 technologies · by team · pay by technology · changes · similar stacks
News
Bernstein Reaffirms Their Hold Rating on Immunovant (IMVT)
Detailed price information for Immunovant Inc (IMVT-Q) from The Globe and Mail including charting and trades.
Read more
Report
Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)
/PRNewswire/ -- A missed primary endpoint took Immunovant (NASDAQ: IMVT) down roughly 6% on September 23, 2026 -- to the stock
Read more
Report
Report
Immunovant ditches lupus for multi-hyphenate inflammatory drug after mid-stage miss
After imeroprubart failed to demonstrate sufficient efficacy in lupus during a Phase 2b trial, Immunovant is moving on from the indication and looking to other high priority programs for the drug in neurology, endocrinology and rheumatology.
Read more
Report
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on...
Read more
Report
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance…...
Read more
Report
Is Immunovant (IMVT) Undervalued After Its Pullback to $37.36?
Immunovant (IMVT) has drawn fresh attention after recent trading left the stock around $37.36, with short term moves weaker but a strong total return profile over the past year and beyond. Recent trading tells a mixed story for Immunovant. Short term shar
Read more
Report
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves' disease (GD), myasthenia gravis (MG),…...
Read more
Report
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
DURHAM, N.C., July 23, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that it will report its financial…...
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
3
Hiring now
1
Countries
2
Busiest office
New York
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
New York
United States
HQ
New York City
1 open roles 100% remote 500-1000 est. staff $150k Avg Salary
hires for Administrative
Durham
United States
Regional office
DURHAM, NC
1000 Park Forty Plaza, Suite 210, Durham, NC 27713
Basel
Switzerland
Regional office
Basel, Switzerland